The role of chemogenomics in the pharmaceutical industry

Drug Development Research

Volumn 73, Issue 7, 2012, Pages 357-364

  Bieler, Michael ^a   Koeppen, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

bioprofile; chemogenomics; pharmaceutical research; polypharmacology; similarity principle; target fishing

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; GLUTATHIONE REDUCTASE; NELFINAVIR; SOMATOSTATIN RECEPTOR 5;

BINDING AFFINITY; DRUG BINDING; DRUG BINDING SITE; DRUG INDUSTRY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; REVIEW;

EID: 84870067237     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21026     Document Type: Review

References (58)

1. Andersson CR, Gustafsson MG, Stroembergsson H,. 2011. Quantitative chemogenomics: machine-learning models of protein-ligand interaction. Curr Top Med Chem (Sharjah, United Arab Emirates) 11: 1978-1993.
2. Beroza P, Damodaran K, Lum RT,. 2005. Target-related affinity profiling: Telik's lead discovery technology. Curr Top Med Chem (Sharjah, United Arab Emirates) 5: 371-381.
3. Beroza P, Villar HO, Wick MM, Martin GR,. 2002. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov Today 7: 807-814.
4. Bock JR, Gough DA,. 2005. Virtual screen for ligands of orphan G protein-coupled receptors. J Chem Inf Model 45: 1402-1414.
5. Bohacek RS, McMartin C, Guida WC,. 1996. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16: 3-50.
6. Caron PR, Mullican MD, Mashal RD, Wilson KP, Su MS, Murcko MA,. 2001. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol 5: 464-470.
7. Christ CD, Mark AE, van Gunsteren WF,. 2010. Basic ingredients of free energy calculations: a review. J Comput Chem 31: 1569-1582.
8. Congreve M, Chessari G, Tisi D, Woodhead AJ,. 2008. Recent developments in fragment-based drug discovery. J Med Chem 51: 3661-3680.
9. Crossley R, Macritchie JA, Slater MJ,. 2011. Thematic analysis: a chemogenomic approach to GPCR drug discovery. Curr Top Med Chem (Sharjah, United Arab Emirates) 11: 1925-1943.
10. Delsuc F, Brinkmann H, Philippe H,. 2005. Phylogenomics and the reconstruction of the tree of life. Nat Rev Genet 6: 361-375.
11. Dixon SL, Villar HO,. 1998. Bioactive diversity and screening library selection via affinity fingerprinting. J Chem Inf Comput Sci 38: 1192-1203.
12. Durrant JD, Amaro RE, Xie L, Urbaniak MD, Ferguson Michael AJ, Haapalainen A, Chen Z, Di Guilmi AM, Wunder F, Bourne PE, et al. 2010. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol 6: 1-8.
13. Fink T, Reymond JL,. 2007. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47: 342-353.
14. Frimurer TM, Hogberg T,. 2011. Drug design of GPCR ligands using physicogenetics and chemogenomics-principles and case studies. Curr Top Med Chem (Sharjah, United Arab Emirates) 11: 1882-1901.
15. Gills JJ, LoPiccolo J, Tsurutani J, Shoemaker RH, Best CJM, bu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, et al. 2007. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13: 5183-5194.
16. Gloriam DE, Foord SM, Blaney FE, Garland SL,. 2009. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J Med Chem 52: 4429-4442.
17. Guba W, Green LG, Martin RE, Roche O, Kratochwil N, Mauser H, Bissantz C, Christ A, Stahl M,. 2007. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. J Med Chem 50: 6295-6298.
18. Hopkins AL,. 2008. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
19. Hoyer D, Hannon JP, Martin GR,. 2002. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554.
20. Hsu N, Cai D, Damodaran K, Gomez RF, Keck JG, Laborde E, Lum RT, Macke TJ, Martin G, Schow SR, et al. 2004. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints. J Med Chem 47: 4875-4880.
21. Jacob L, Hoffmann B, Stoven V, Vert JP,. 2008. Virtual screening of GPCRs: an in silico chemogenomics approach. BMC Bioinformatics 9: 363-379.
22. Jacoby E,. 2011. Computational chemogenomics. Wiley Interdiscip Rev: Comput Mol Sci 1: 57-67.
23. Johnson MA, Maggiora GM,. 1990. Concepts and Applications of Molecular Similarity. New York: John Wiley & Sons.
24. Kauvar LM, Higgins DL, Villar HO, Sportsman JR, Engqvist-Goldstein A, Bukar R, Bauer KE, Dilley H, Rocke DM,. 1995. Predicting ligand binding to proteins by affinity fingerprinting. Chem Biol 2: 107-118.
25. Keiser MJ, Irwin JJ, Shoichet BK,. 2010. The chemical basis of pharmacology. Biochemistry 49: 10267-10276.
26. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK,. 2007. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
27. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al. 2009. Predicting new molecular targets for known drugs. Nature (London, UK) 462: 175-181.
28. Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young MP, Jenkins JL, Glick M, Glen RC, et al. 2011. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics 74: 2554-2574.
29. Kubinyi H, Mueller G, editors. 2004. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective. Weinheim, Germany: Wiley-VCH, 463 p.
30. Leis S, Schneider S, Zacharias M,. 2010. In silico prediction of binding sites on proteins. Curr Med Chem 17: 1550-1562.
31. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DVS, Hertzberg RP, Janzen WP, Paslay JW, et al. 2011. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10: 188-195.
32. Maggiora GM,. 2006. On outliers and activity cliffs-why QSAR often disappoints. J Chem Inf Model 46: 1535.
33. Martin RE, Green LG, Guba W, Kratochwil N, Christ A,. 2007. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J Med Chem 50: 6291-6294.
34. Matter H, Sotriffer C,. 2011. Applications and success stories in virtual screening. In:, Sotriffer C, editor. Virtual Screening: Principles, Challenges, and Practical Guidelines. Weinheim, Germany: Wiley-VCH, p 319-358.
35. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV,. 2009. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst 5: 1051-1057.
36. Michel J, Essex JW,. 2010. Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J Comput Aided Mol Des 24: 639-658.
37. Morphy R, Rankovic Z,. 2005. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48: 6523-6543.
38. Nair R, Liu J, Soong TT, Acton TB, Everett JK, Kouranov A, Fiser A, Godzik A, Jaroszewski L, Orengo C, et al. 2009. Structural genomics is the largest contributor of novel structural leverage. J Struct Funct Genomics 10: 181-191.
39. Ning X, Karypis G,. 2011. In silico structure-activity-relationship (SAR) models from machine learning: a review. Drug Dev Res 72: 138-146.
40. Receveur JM, Bjurling E, Ulven T, Little PB, Norregaard PK, Hogberg T,. 2004. 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg Med Chem Lett 14: 5075-5080.
41. Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, Haggarty SJ, Kokel D, Rubin LL, Peterson RT, et al. 2010. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science (Washington, DC, US) 327: 348-351.
42. Rognan D,. 2010. Structure-based approaches to target fishing and ligand profiling. Mol Inf 29: 176-187.
43. Sotriffer C, editor. 2011. Virtual Screening: Principles, Challenges, and Practical Guidelines. Weinheim, Germany: Wiley-VCH, 519 p.
44. Sotriffer C, Matter H,. 2011. The challenge of affinity prediction: scoring functions for structure-based virtual screening. In:, Sotriffer C, editor. Virtual Screening: Principles, Challenges, and Practical Guidelines. Weinheim, Germany: Wiley-VCH, p 179-221.
45. Stumpfe D, Bajorath J,. 2012. Exploring activity cliffs in medicinal chemistry. J Med Chem 55: 2932-2942.
46. Surgand JS, Rodrigo J, Kellenberger E, Rognan D,. 2006. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62: 509-538.
47. Todeschini R, Consonni V,. 2009. Molecular Descriptors for Chemoinformatics. Weinheim, Germany: Wiley-VCH, 1220 p.
48. van der Horst E, Peironcely JE, Ijzerman AP, Beukers MW, Lane JR, van Vlijmen HW, Emmerich MT, Okuno Y, Bender A,. 2010. A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinformatics 11: 316-328.
49. van der Horst E, Peironcely JE, van Westen GJP, van den Hoven OO, Galloway WRJD, Spring DR, Wegner JK, van Vlijmen HWT, Ijzerman AP, Overington JP, et al. 2011. Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr Top Med Chem (Sharjah, United Arab Emirates) 11: 1964-1977.
50. van Westen GJP, Wegner JK, IJzerman AP, van Vlijmen HWT, Bender A,. 2011. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. Med Chem Commun 2: 16-30.
51. Weill N,. 2011. Chemogenomic approaches for the exploration of GPCR space. Curr Top Med Chem (Sharjah, United Arab Emirates) 11: 1944-1955.
52. Weill N, Rognan D,. 2009. Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J Chem Inf Model 49: 1049-1062.
53. Weisel M, Proschak E, Schneider G,. 2007. PocketPicker: analysis of ligand binding-sites with shape descriptors. Chem Cent J 1: 1-17.
54. Willett P, Barnard JM, Downs GM,. 1998. Chemical similarity searching. J Chem Inf Comput Sci 38: 983-996.
55. Xie L, Bourne PE,. 2007. A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics 8: 1-13.
56. Xie L, Evangelidis T, Xie L, Bourne PE,. 2011. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir. PLoS Comput Biol 7: 1-13.
57. Xie L, Xie L, Bourne PE,. 2009. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics 25: i305-i312.
58. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, et al. 2008. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 4: 59-68.